Friday, July 20, 2018
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares
(July 11, 2018)

BASEL, Switzerland, July 11, 2018 /PRNewswire/ --†Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases today announced that it has commenced an underwritten public offering of $75 million of its common shares. All of the common shares are being offered by Myovant. In connection with this offering, Myovant expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares in the offering on the same terms and conditions. Myovant currently intends to use the net proceeds from the offering primarily to fund its clinical development programs, preparations for the potential commercial launch of relugolix, as well as for working capital and other general corporate purposes.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. JMP Securities LLC and Robert W. Baird & Co. Incorporated are acting as co-managers.† The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.†

A shelf registration statement relating to the offered common shares was filed with the Securities and Exchange Commission (SEC), and was declared effective on March 23, 2018.† A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website, located at† Copies of the preliminary prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at [email protected] or by phone at (866) 803-9204, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected] or by phone (866) 471-2526 and Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] or by phone at (888) 603-5847.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful.

About Myovant

Myovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's goal is to be the leading global biopharmaceutical company focused on treating women's health and endocrine diseases in areas of high unmet medical need.

Forward-Looking Statements
This announcement contains forward-looking statements, including statements relating to Myovant's expectations regarding the completion, timing and size of the proposed public offering, and use of proceeds. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and Myovant cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Myovant will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Myovant and its business can be found in the "Risk Factors" section of Myovant's Form 10-K, filed with the SEC on June 7, 2018, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC. Myovant undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Myovant's expectations.

Frank Karbe
Chief Financial Officer
Myovant Sciences
[email protected]

Julie Normart
[email protected]

Cision View original content with multimedia:

SOURCE Myovant Sciences

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc.,Surgery,Business,Email,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

  • Mesothelioma is a Deadly Cancer and itís Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally -

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines